Investing in biotechnology stocks can be a lucrative way to capitalize on the potential for innovation and growth in this rapidly evolving industry. However, finding affordable biotech stocks that offer a good return on investment can be a challenge. Here are some cheap biotechnology stocks to consider for 2022.
- Athersys Inc. (ATHX) – With a market capitalization of around $360 million, Athersys is a small-cap biotech company that is focused on developing regenerative therapies for acute and chronic conditions. The company’s lead product, MultiStem, is in clinical trials for several indications, including stroke, acute respiratory distress syndrome, and traumatic injury.
- Adaptimmune Therapeutics plc (ADAP) – Adaptimmune is a mid-cap biotech company that is developing cell therapies for cancer. The company’s lead product candidate, ADP-A2M4, is in clinical trials for the treatment of solid tumors. With a market capitalization of around $800 million, Adaptimmune offers an affordable entry point into the promising field of cancer cell therapies.
- IVERIC bio, Inc. (ISEE) – IVERIC bio is a small-cap biotech company that is focused on developing gene therapies for inherited retinal diseases. The company’s lead product candidate, Zimura, is in clinical trials for the treatment of geographic atrophy, a leading cause of blindness in the elderly. With a market capitalization of around $300 million, IVERIC bio has the potential for significant growth as gene therapy continues to gain momentum in the biotechnology industry.
- Zomedica Corp. (ZOM) – Zomedica is a micro-cap biotech company that is focused on developing veterinary diagnostic and treatment products. The company’s lead product, TRUFORMA, is a point-of-care diagnostic platform that is expected to launch in 2022. With a market capitalization of around $100 million, Zomedica offers a high-risk, high-reward investment opportunity in the growing field of animal healthcare.
Investing in biotechnology stocks can be risky, and it is important to conduct thorough research and analysis before making any investment decisions. However, these cheap biotechnology stocks offer the potential for significant growth in 2022 and beyond, making them worth considering for investors with a high tolerance for risk.